IFS
IMUC

Ifrah Financial Services’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Ifrah Financial Services’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-463
Closed -$2K – 208
2016
Q3 		$2K Hold
463
– – ﹤0.01% 192
2016
Q2 		$4K Hold
463
– – ﹤0.01% 196
2016
Q1 		$5K Hold
463
– – ﹤0.01% 193
2015
Q4 		$7K Hold
463
– – ﹤0.01% 189
2015
Q3 		$8K Hold
463
– – ﹤0.01% 195
2015
Q2 		$9K Hold
463
– – ﹤0.01% 202
2015
Q1 		$9K Hold
463
– – ﹤0.01% 203
2014
Q4 		$14K Hold
463
– – 0.01% 198
2014
Q3 		$16K Hold
463
– – 0.01% 205
2014
Q2 		$21K Hold
463
– – 0.01% 200
2014
Q1 		$23K Hold
463
– – 0.01% 199
2013
Q4 		$17K Sell
463
-250
-35% -$23.7K 0.01% 192
2013
Q3 		$73K Buy
+713
New +$78.3K 0.04% 106

Other funds holding IMUC

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $578M AUM 49.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Ifrah Financial Services's IMUC Position: Q4 2016 in Review

Ifrah Financial Services sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2016, closing a stake of 463 shares — an estimated $2K sold.

Ifrah Financial Services first reported a position in IMUC in Q3 2013 and held it in 13 quarters. The position peaked at $73K in Q3 2013. 16 funds tracked by Wall St. Rank hold IMUC as of Q4 2016.

  • Ifrah Financial Services reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2016 after selling out during the quarter.
  • Ifrah Financial Services sold 463 ImmunoCellular Therapeutics, Ltd. shares in Q4 2016, an estimated $2K.
  • Ifrah Financial Services first reported a position in ImmunoCellular Therapeutics, Ltd. in Q3 2013 and held it in 13 quarters.
  • Ifrah Financial Services's ImmunoCellular Therapeutics, Ltd. position peaked at $73K in Q3 2013.
  • 16 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2016.

Based on Ifrah Financial Services's 13F filing for Q4 2016, filed 8 Feb 2017.